Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03800979|
Recruitment Status : Recruiting
First Posted : January 11, 2019
Last Update Posted : January 30, 2019
|Condition or disease||Intervention/treatment||Phase|
|Alopecia Areata||Drug: Tofacitinib||Phase 4|
Alopecia areata (AA) or spot baldness, is a condition in which hair falls off from areas of the body. It often happens on the scalp, causing a few bald spots and it may result in psychological stress even though people are generally healthy. AA is believed to be an autoimmune disease progressing from a breach in the immune privilege of the hair follicles that causes hair to fall out in small patches, it may remain unnoticeable until the patches eventually connect and then become noticeable. It can develop slowly, and also recur after years between occurrences.
By standard AA treatment guideline, DPCP is the first treatment protocol and may follow with anthralin or minoxidil. This oldy but goody treatment gives a good result of 75% in spotty hair loss and 25% in total baldness. The new invention of treatment has been introduced in the past 2 years by using JAK inhibitor, an oral medicine such as Tofacitinib and Ruxolitinib. This treatment gives a good outcome so far in this short period of time, 54-81.9% of patients had over 50% increase of hair grows over the original protocol. The theory is that JAK inhibitors would inhibit interferon-gamma and interleukin-15 signal between white blood cell and hair follicle which reducing the rate of destroying hair follicles.
The investigators propose the study to assess the safety and efficacy of Tofacitinib for extensive and recalcitrant AA and to evaluate the economic impact effecting the AA patients. Tofacitinib is an expensive medicine and needed to be taken up to 6 months to finish the course to have a best outcome so it is not a popular choice of AA treatment at present time unless it can show a promising result in recalcitrant AA.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||19 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This is a Cohort study which all recruited volunteers will receive Tofacitinib for total of 24 weeks. The 19 volunteers are mixed male and female Thais who suffer from severe AA over 50% of the entire scalp.|
|Masking:||None (Open Label)|
|Official Title:||Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata|
|Actual Study Start Date :||January 12, 2019|
|Estimated Primary Completion Date :||September 30, 2020|
|Estimated Study Completion Date :||September 30, 2020|
All participants will take Tofacitinib 5 mg twice daily for 24 weeks to treat extensive and recalcitrant alopecia areata.
Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
Other Name: Xeljanz
- The area of hair loss either on the scalp or body is measured and recorded using SALT score. [ Time Frame: 48 weeks ]Severity of Alopecia Tool (SALT) is a measurement procedure used by dermatologist to determine percentage of scalp hair loss. SALT system divides the scalp in 4 areas: Top has 4 sections of 10% total are 40%, back has 4 sections of 6% total are 24% and the 2 sides, left and right, each has 2 sections of 4% and 2 sections of 5% total of 18% and 36% combined. At beginning, the area of hair loss would be measured by checking each area for hair loss and determine the bald spots combined per SALT scale then keep record as SALT base line (SALTBL).
- Side effect from Tofacitinib [ Time Frame: 48 weeks ]Patients will come back for follow up after 1st treatment at the time set by researcher (vary differently per cases), we call this measurement SALT follow up (SALTF/U). SALT score is calculated into percentage as the formula "SALTBL minus SALTF/U then divide by SALTBL and time 100"=% change from baseline. All volunteers will be evaluated by SALT score every 4 weeks after starting the treatment. All volunteers will have total of 24 weeks treatments unless the condition is improved to satisfaction before or having intolerable side effect. Follow up will be at 28th,36th and 48th week.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03800979
|Contact: Chinmanat Tangjaturonrusamee, MDfirstname.lastname@example.org|
|Contact: Chinmanat Tangjaturonrusameeemail@example.com|
|Institute of Dermatology||Recruiting|
|Contact: Chinmanat Tangjaturonrusamee, M.D.|
|Principal Investigator:||Chinmanat Tangjaturonrusamee, MD||Institute of Dermatology|